Add BrightSurf on Google Email

JCI table of contents: March 15, 2007

Researchers from the University of Washington developed a new antibacterial strategy using Gallium, which inhibits the growth of Pseudomonas aeruginosa and prevents biofilm formation. Additionally, studies suggest that Nutlin-3a may reactivate the p53 pathway to treat Kaposi's sarcoma virus-induced lymphomas. Another study found that a...

SourceJCI Journals·JournalJournal of Clinical Investigation·DateMar 15, 2007

Therapeutic unshackles p53 and causes tumor regression

Researchers discovered Nutlin-3a induces apoptosis in human PEL cell lines by disrupting LANA-p53 interaction, causing substantial tumor regression in mice with established PEL. This reactivation of the p53 pathway may provide a viable therapeutic option for individuals with KSHV-induced lymphomas.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateMar 15, 2007

Therapeutic peptide frees the protein p73 to kill tumor cells

Researchers have discovered a peptide that can free the protein p73, which induces tumor cell death, and effectively kills both p53-sufficient and p53-deficient human tumor cell lines. The study suggests targeting the p73-mediated pathway could provide a new avenue for developing anticancer therapeutics.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateMar 8, 2007

A new jump start for aging blood vessels

Researchers found that inactivating TNFa significantly reduced blood vessel impairment and cell death in aged vessels, suggesting a link between increased TNFa levels and cardiovascular disease. The study's findings could lead to the development of new treatments for age-related vascular diseases.

SourceAmerican Journal of Pathology·JournalAmerican Journal Of Pathology·DateDec 28, 2006

New treatment hope for systemic sclerosis

Researchers discovered that imatinib mesylate inhibits the synthesis of extracellular matrix proteins and prevents tissue fibrosis in patients with systemic sclerosis. The study provides promising results for a new treatment approach, but more extensive studies are needed to confirm its efficacy.

SourceWiley·JournalArthritis & Rheumatism·DateDec 28, 2006

Unfolded proteins may protect cells from dying

Research from Rockefeller University reveals that unfolded protein response serves a protective role, shielding cells from death. The study focuses on autosomal dominant retinitis pigmentosa, where unfolded proteins accumulate in the endoplasmic reticulum, indicating their protective mechanism.

SourceRockefeller University·JournalThe EMBO Journal·DateDec 22, 2006

Pain relief effectiveness down to mind-set?

A study by the Human Pain Research Group at the University of Manchester found that individuals' expectations and beliefs play a crucial role in their response to pain relief. The researchers discovered that 67% of volunteers who expected pain relief continued to perceive less pain after applying a placebo cream, highlighting the power...

SourceUniversity of Manchester·JournalPain·DateDec 21, 2006

JCI table of contents: November 16, 2006

Researchers suggest repairing abnormal blood vessels in retinopathy using adult bone marrow–derived myeloid progenitor cells. Dendritic cells form part of granuloma walls containing Listeria monocytogenes, maintaining integrity through immunosuppressive protein IDO.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateNov 16, 2006

Peer and family support tops needs of young adult cancer survivors

A study published in CANCER reveals that adolescent and young adult cancer patients value social connections with peers as a high priority, contrary to physician beliefs. Researchers found that meeting other young people who share a common experience helps address concerns such as coping with uncertainty and body changes.

SourceWiley·JournalCancer·DateNov 13, 2006

Mayo Clinic Cancer Center prostate SPORE grant renewed

The Mayo Clinic Cancer Center's Specialized Programs of Research Excellence (SPORE) grant has been renewed for an additional five years. The grant will fund translational research projects aimed at identifying biomarkers to predict response to therapy and developing non-invasive imaging options for diagnosis and treatment.

Cancer survival compromised by poor staging methods

A study found that less than one-third of gastric cancer patients had adequate lymph node assessments, leading to compromised survival. Median survival in regions with the highest ALNA rate was 33 months, while in regions with the lowest rate it was only 17 months.

SourceWiley·JournalCancer·DateSep 25, 2006